The NIH has approved four new human embryonic stem cell lines for federally funded research. The lines, from CIRM-funded BioTime, have one thing going for them that many other lines don't. They were developed in compliance with Good Manufacturing Practice requirements, which is a critical step for developing a transplantation therapy.